Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Zydus (Details)

v3.20.2
Licensing and Other Arrangements - Zydus (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 03, 2020
USD ($)
item
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Licensing and other arrangements          
Revenue from contracts with customers   $ 53 $ 625 $ 553 $ 8,651
Zydus | License Agreement          
Licensing and other arrangements          
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events $ 500        
Maximum amount receivable upon achievement of commercial milestones $ 23,500        
Number of performance obligations | item 1        
Contract assets   0   0  
Contract liabilities   0   0  
Capitalized contract costs   $ 0   0  
Revenue from contracts with customers       $ 0